Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
2020 · Journal for ImmunoTherapy of Cancer · 158 citations
https://doi.org/10.1136/jitc-2020-001240
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
213
Citations
5
h-index
3
i10-index
Poshita Kumari Seesaha is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cholangiocarcinoma and Gallbladder Cancer Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 5, co-authored 8 publications.
ORCID: 0000-0002-6182-4842Click to start Chat